Nanogen Selected as Exclusive COVID-19 Vaccine R&D Institution by Vietnamese Government

[Asia Economy Reporter Yoo Hyun-seok] NanoGen, the only biosimilar company within the Association of Southeast Asian Nations (ASEAN) invested by NextScience, announced on the 21st that it has been selected by the Vietnamese Ministry of Science and Technology as the exclusive research and development institution for COVID-19 vaccine development (Project title: Production of COVID-19 vaccine based on virus-like particles applying recombinant protein technology).

The cost for NanoGen's COVID-19 (SARS-CoV-2) vaccine development is expected to be supported by the Vietnamese government, and preclinical trials including primates will be conducted in collaboration with the National Institute of Hygiene and Epidemiology of Vietnam.

Founded in 1997, NanoGen is a Vietnamese biosimilar company that succeeded in developing Peg-Interferon, a hepatitis treatment, in 2012, contributing to reducing the prevalence of hepatitis among Vietnamese people. Currently, based on its excellent research capabilities, it is developing various biosimilar products. The breast cancer treatment 'Trastuzumab' is expected to complete clinical trials in Vietnam this year, and clinical trials for the anemia treatment new drug 'Darbepoetin' are actively underway.

NanoGen is included as one of the members of HBS (HLB Bio eco-System), led by HLB, and has concretized partnerships through mutual investments, new drug development, and licensing with several bio-affiliated companies within the HLB Group. It is also building a collaborative system through various methods such as project technology cooperation and joint development.

HLB has established HBS by uniting bio companies developing new drugs in various fields such as targeted anticancer drugs, immuno-oncology drugs, cell therapies, sepsis, vaccines, and brain tumor treatments through its U.S. subsidiary Eleva, Immunomic Therapeutics, and affiliated companies. HBS is a system that integrates the capabilities of each affiliated company related to new drug development processes, production, regulations, approvals, marketing, and networks under the name of HLB. HLB plans to minimize trial and error in the new drug development process through HBS.

This content was produced with the assistance of AI translation services.